Modified REZ BFM 87 Protocol in Relapsed Childhood ALL: A Preliminary Report

  • T. Urasinski
  • J. Peregud-Pogorzelski
  • A. Brodkiewicz
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)


As reported elsewhere, treatment results in childhood acute lymphoblastic leukemia (ALL) achieved in our institution are still unsatisfactory (T. Urasinski and J. Pogorazelski, unpublished data). After the median follow-up time of 33 months the probability of event-free survival (p-EFS) is 0.429 and relapses are the main reason for treatment failures. Thus the problem of relapsed ALL is of vital importance for us.


Acute Lymphoblastic Leukemia Late Relapse Childhood Acute Lymphoblastic Leukemia Massive Gastrointestinal Bleeding Bone Marrow Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chessells JM, Breatnach F (1981) Late marrow recurrences in childhood acute lymphoblastic leukaemia. Br Med J 238: 749–751CrossRefGoogle Scholar
  2. 2.
    Chessells JM, Cornbleet M (1979) Combination chemotherapy for bone marrow relapse in childhood lymphoblastic leukaemia ( ALL ). Med Pediatr Oncol 6: 359–365PubMedCrossRefGoogle Scholar
  3. 3.
    Niethammer D, Dopfer R, Klingebiel Tet al. (1989) Actual role and perspectives of BMT in children. Bone Marrow Tranplantat 4: 7–11Google Scholar
  4. 4.
    Rivera GK, Buchanan G, Bovett JM et al. (1986) Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. N Engl J Med 315: 273–278PubMedCrossRefGoogle Scholar
  5. 5.
    Henze G. Buchmann S, Fengler R et al. (1987) The BFM relapse studies in childhood ALL: concepts of two multicenter trials and results after 2 1/2 years. Haematol Blood Transfus 30: 147–155PubMedGoogle Scholar
  6. 6.
    Henze G (1986) Studie zur Behandlung von Kindern mit Rezidiv einer akuten lymphoblastischen Leukämie. pp 5–15Google Scholar
  7. 7.
    Wendt F, Maschmeyer G (1987) Infection prevention and immediate antibiotic therapy in the neutropenic patient. Haematol Blood Transfus 30: 175–181PubMedGoogle Scholar
  8. 8.
    Bleyer WA (1978) The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 41: 36–51PubMedCrossRefGoogle Scholar
  9. 9.
    Rivera GK, Santana V, Mahmoud H et al. (1989) Acute lymphoblastic leukemia in childhood: the problem of relapses. Bone Marrow Transplant 4 [Suppl 1]: 80–85PubMedGoogle Scholar
  10. 10.
    Henze G, Fengler R, Hartmann R et al. (1990) BFM Group treatment results in relapsed childhood ALL. Haematol Blood Transfus 33: 619–626PubMedGoogle Scholar
  11. 11.
    Fengler R, Hartmann R, Bode U et al. (1990) Risk of CNS relapse after systemic relapse of childhood ALL. Haematol Blood Transfus 33: 511–515PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • T. Urasinski
    • 1
  • J. Peregud-Pogorzelski
    • 1
  • A. Brodkiewicz
    • 1
  1. 1.First Pediatric DepartmentPomeranian Medical AcademySzczecinPoland

Personalised recommendations